Alescat, autologous lymphocyte-based therapy for the treatment of solid cancers

Alecsat cells are CD8-positive cytotoxic T lymphocytes  and natural killer cells. These cells can specifically recognize and kill cancer cells. Following isolation of the  CD8-positive cytotoxic T lymphocytes  and natural killer  cells from patient blood, they are returned to the patient to boost an immune response against the cancer cells. Preliminary clinical phase I/II data from 13 late-stage prostate cancer patients show that Alescat treatment is well tolerated and has no side effects. In most of the patients, the treatment also showed indications of clinical effect.